S53P4生物活性玻璃颗粒用于乳突及上鼓室填塞术后的CT与MRI表现
前瞻性纳入2013年5月至2015年12月行乳突及上鼓室S53P4生物活性玻璃颗粒填塞术的70例患者,术后1年行颞骨HRCT评估颗粒的衰减值、均匀性和骨整合,术中发现胆脂瘤者加做MRI(含非平面回波扩散加权序列)。HRCT上颗粒平均衰减值为888.34±166.10 HU,表现均匀伴部分骨整合;T2加权及扩散加权MRI上呈低信号,与胆脂瘤表现始终不同,随访延长未见衰减值或信号改变。
要点
- HRCT上BG颗粒平均衰减值888.34±166.10 HU,高于胆脂瘤、低于乳突骨质。
- BG颗粒在非平面回波扩散加权序列及T2加权像上呈低信号,与胆脂瘤表现不同。
- BG颗粒填塞的容积与影像表现随时间保持稳定。
核心结论
- 使用HRCT和MRI对S53P4生物活性玻璃颗粒行乳突及上鼓室填塞术后患者进行影像随访是有效的,BG颗粒特有的影像表现有助于检出胆脂瘤和其他潜在并发症。
研究设计与样本
- 前瞻性、非对照临床研究,纳入2013年5月至2015年12月行乳突及上鼓室填塞术的患者70例,术后1年行颞骨HRCT,术中发现胆脂瘤者加做MRI(至少包括增强前后T1加权、T2加权及轴位非平面回波扩散加权序列)。
关键影像表现/征象
- 术后1年HRCT示BG颗粒平均衰减值为888.34±166.10 HU。
- 填塞区多表现为均匀,伴部分骨整合。
- BG颗粒在T2加权成像和扩散加权MRI上呈低信号,与胆脂瘤表现始终不同。
- 延长随访显示BG颗粒的衰减值和信号与术后1年影像相比无改变。
诊断标准与关键数值
- HRCT上BG颗粒衰减值高于胆脂瘤、低于乳突骨质。
- MRI上BG颗粒在非平面回波扩散加权序列和T2加权像呈低信号,并可见对比增强,据此与胆脂瘤鉴别。
临床应用与阅片要点
- 术后1年颞骨HRCT可用于评估BG颗粒的衰减值、均匀性和骨整合情况。
- 术中发现胆脂瘤者,术后1年MRI加做非平面回波扩散加权序列有助于检出残留胆脂瘤及其他颞骨病变。
- 阅片时注意BG颗粒在扩散加权和T2加权像上的低信号特征,以与胆脂瘤鉴别。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the appearance of mastoid and epitympanic obliteration using S53P4 bioactive glass (BG) granules in high-resolution computed tomography (HRCT) and MRI.
MATERIALS AND METHODS: Patients undergoing mastoid and epitympanic obliteration between May 2013 and December 2015 were prospectively included in an uncontrolled clinical study. All patients underwent a temporal HRCT scan 1 year after surgery, aimed at evaluating the attenuation, homogeneity, and osseointegration of the BG granules, as well as the ventilation of the middle ear and the volume of the obliterated paratympanic spaces. If a cholesteatoma was found during surgery, additional MRI, including at least pre- and post-contrast T1-weighted, T2-weighted, and axial non-echo-planar diffusion-weighted (DW) sequences, was performed 1 year after surgery, to study the normal signal of the BG granules and the presence of residual cholesteatoma and/or other temporal bone pathologies.
RESULTS: Seventy cases were included. On 1-year HRCT, the mean attenuation of the BG granules was 888.34 ± 166.10 HU. The obliteration was found to be mostly homogeneous with partial osseointegration. The appearance of the BG granules having a low-intensity signal in T2-weighted imaging and DW MRI was always different from the appearance of cholesteatoma. A longer follow-up has shown no attenuation or signal modification of the BG granules compared with the 1-year imaging.
CONCLUSION: Radiological follow-up of patients operated on with mastoid and epitympanic obliteration using BG granules is effective using both HRCT and MRI. A cholesteatoma and/or other potential complications could easily be detected due to the specific radiological appearance of the BG granules.
KEY POINTS: • The appearance of mastoid and epitympanic obliteration by S53P4 bioactive glass (BG) granules on high-resolution computed tomography (HRCT) scans was homogeneous with an attenuation significantly higher than the attenuation of cholesteatoma and lower than mastoid bone attenuation. • The granules have a low-intensity signal on non-echo-planar diffusion-weighted sequences and on T2-weighted images and present contrast enhancement allowing the differential diagnosis with cholesteatoma and effective for the detection of other underlying temporal bone pathologies. • The volume and radiological appearance of the obliteration appear to be stable with time.
引用
- Bernardeschi D, Law-Ye B, Bielle F, et al. Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance. Eur Radiol. 2019. PMID: 30888487. doi:10.1007/s00330-019-06120-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。